CIRM Funded Clinical Trials

Anti-HIV duoCAR-T cell therapy for HIV infection


Steven Deeks
Disease Area: 
Investigator:
CIRM Grant:
CLIN2-12090 (Pre-Active)
Award Value:
$8,970,732
Trial Stage: 
Phase 1/2
Trial Status: 
Launching
Targeted Enrollment:
N/A
Details: 

The University of California San Francisco (UCSF) is conducting a clinical trial that modifies a patient’s own immune cells in order to treat and potentially cure HIV. 

Current treatment of HIV involves the use of long-term antiretroviral therapy (ART).  However, many people are not able to access and adhere to long-term ART.

The team will take a patient’s blood and extract T cells, a type of immune cell.  The T cells are then genetically modified to express two different chimeric antigen receptors (CAR), which enable the newly created duoCAR-T cells to recognize and destroy HIV infected cells.  The modified T cells are then reintroduced back into the patient.

The goal of this one time therapy is to act as a long-term control of HIV with patients no longer needing to take ART, in effect a form of HIV cure.  This approach would also address the needs of those who are not able to respond to current approaches, which is estimated to be 50% of those affected by HIV globally. 

Design: 

This is a Phase I/IIA clinical trial. 

Goal: 

To evaluate safety and tolerability.